Institution identification

PURI

https://redirect.ema.europa.eu/resource/3331387

Institution ID

3331387

Institution full name and acronym

Karolinska Institutet

Institution countries

Sweden

Type of institution

Educational Institution

ENCePP partner

No
Institution details
Experience with collecting data directly from individual patients or respondents:
No
Interest in carrying out research that is funded by pharmaceutical companies:
No

Studies conducted by the institution

A Nationwide Post-Marketing Study on the Safety of Abatacept Treatment in Sweden Using the SRQ Register
An Active Surveillance, Post Authorization Safety Study (PASS) to Estimate Incidence Rates of Serious Infection, Malignancy, Cardiovascular (CV) and Other Safety Events of Interest among all Patients Treated with Ruxience for Rheumatoid Arthritis (RA) within the Swedish, Population based, Anti Rheumatic Treatment in Sweden (ARTIS) Register
Description of international collaboration in the area of medicines use and effects in COVID-19 affected pregnancies (CONSIGN-International))
Non-interventional Post-Authorisation Safety Study of Burosumab in the Treatment of Children >1 year of age, Adolescents and Adults with X-Linked Hypophosphataemia (XLH PASS)
Non-interventional post-authorization cohort safety study evaluating the effectiveness of the additional risk minimization measures for filgotinib (Jyseleca®) use in patients with moderate to severe active rheumatoid arthritis within European registries
Non-interventional post-authorization safety study of filgotinib in the treatment of patients with moderate to severe active rheumatoid arthritis within European registries
Population-based retrospective nested case-control study evaluating effectiveness of GARDASIL™ against adult-onset recurrent respiratory papillomatosis in Sweden (V503-088)
PRAXIS - A real world longitudinal study of asthma and COPD in primary and secondary care